In Vivo Quantitative Assessment of Gestational Choriocarcinoma Development and Progression Using Luminescent Trophoblast Cells.
Follow-up of choriocarcinoma dissemination
Gestational choriocarcinoma
Orthotopic model
Quantification of choriocarcinoma growth
Quantitative assessment of gestational choriocarcinoma
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2024
2024
Historique:
medline:
30
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
ppublish
Résumé
Gestational trophoblastic diseases (GTD) are a group of pregnancy-related disorders representing rare human tumors. Among GTD is the gestational choriocarcinoma (CC), which is a highly malignant gestational trophoblastic tumor that causes high mortality without timely treatment. The incidence of CC is about 1 in 50,000 pregnancies in developed countries and even higher in developing countries. CC developed from molar pregnancies exhibits even higher incidence rates (3-20 in 1000 pregnancies). In the present invention, we developed the first orthotopic animal model of CC. We demonstrate how to mimic the development of this cancer and observe rapid metastasis, which is seen in CC patients, by injecting the luciferase-positive JEG-3 (JEG-3-Luc) cells directly in the placenta of gravid SCID mice. Gravid mice were injected at 7.5 days post coitus (dpc) and followed throughout gestation to assess the parameters of CC development and metastasis. Mice imaged at day 19.5 dpc showed placental tumor development and large sites of metastases in the liver, spleen, lung, and peritoneum. This finding emphasizes the importance of placental vascularization in the rapid dissemination of tumor cells. Morphological analyses and histopathological examinations were performed to confirm JEG-3 cell dissemination in different organs of the gravid mice. This is the first time a CC model was developed by injection of tumor cells within the placenta. This technique offers a new tool to study tumor progression with strong perspectives to test anti-tumor agents in vivo.
Identifiants
pubmed: 38019392
doi: 10.1007/978-1-0716-3495-0_6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
77-85Informations de copyright
© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Froeling FE, Seckl MJ (2014) Gestational trophoblastic tumours: an update for 2014. Curr Oncol Rep 16(11):408
doi: 10.1007/s11912-014-0408-y
pubmed: 25318458
Stevens FT et al (2015) Gestational trophoblastic disorders: an update in 2015. Geburtshilfe Frauenheilkd 75(10):1043–1050
doi: 10.1055/s-0035-1558054
pubmed: 26556906
pmcid: 4629994
Boufettal H et al (2014) Gestational choriocarcinoma at Ibn Rochd Hospital, Casablanca, 2004–2010. East Mediterr Health J 19(Suppl 3):S208–S212
pubmed: 24995750
Cisse CT et al (2002) Choriocarcinoma in Senegal: epidemiology, prognosis and prevention. Gynecol Obstet Fertil 30(11):862–869
doi: 10.1016/S1297-9589(02)00456-3
pubmed: 12476691
Altieri A et al (2003) Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol 4(11):670–678
doi: 10.1016/S1470-2045(03)01245-2
pubmed: 14602247
Smith HO (2003) Gestational trophoblastic disease epidemiology and trends. Clin Obstet Gynecol 46(3):541–556
doi: 10.1097/00003081-200309000-00006
pubmed: 12972736
Savage P et al (2015) Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome. Gynecol Oncol 137(1):73–76
doi: 10.1016/j.ygyno.2015.01.530
pubmed: 25598530
Foulmann K et al (2006) What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence. Gynecol Oncol 102(1):103–110
doi: 10.1016/j.ygyno.2006.02.038
pubmed: 16624388
Lurain JR, Singh DK, Schink JC (2006) Role of surgery in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med 51(10):773–776
pubmed: 17086805
Lurain JR, Singh DK, Schink JC (2006) Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. J Reprod Med 51(10):767–772
pubmed: 17086804
Cagayan MS, Lu-Lasala LR (2006) Management of gestational trophoblastic neoplasia with metastasis to the central nervous system: a 12-year review at the Philippine General Hospital. J Reprod Med 51(10):785–792
pubmed: 17086807
Soper JT (2003) Role of surgery and radiation therapy in the management of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol 17(6):943–957
doi: 10.1016/S1521-6934(03)00091-9
pubmed: 14614891
Bibby AC, Litchfield DW (2005) The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2beta. Int J Biol Sci 1(2):67–79
doi: 10.7150/ijbs.1.67
pubmed: 15951851
pmcid: 1142214
Fluegen G et al (2017) Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments. Nat Cell Biol 19(2):120–132
doi: 10.1038/ncb3465
pubmed: 28114271
pmcid: 5342902
Sasaki S, Sasaki Y, Iino K (2010) Recurrent gestational trophoblastic disease in a case of suspected quiescent gestational trophoblastic disease: a case report. J Reprod Med 55(7–8):317–320
pubmed: 20795345
Lehmann S et al (2017) Hypoxia induces a HIF-1-dependent transition from collective-to-amoeboid dissemination in epithelial cancer cells. Curr Biol 27(3):392–400
doi: 10.1016/j.cub.2016.11.057
pubmed: 28089517
Abi Nahed R et al (2022) Role of NLRP7 in normal and malignant trophoblast cells. Biomedicine 10(2):252
Reynaud D et al (2021) NLRP7 promotes choriocarcinoma growth and progression through the establishment of an immunosuppressive microenvironment. Cancers (Basel) 13(12):2999
doi: 10.3390/cancers13122999
pubmed: 34203890
Traboulsi W et al (2017) Antagonism of EG-VEGF receptors as targeted therapy for choriocarcinoma progression in vitro and in vivo. Clin Cancer Res 23(22):7130–7140
doi: 10.1158/1078-0432.CCR-17-0811
pubmed: 28899975